Evidence has been presented to show that a second dose of suxamethonium is capable of producing a severe bradycardia in man. This response may be effectively prevented by the prior administration of certain non-depolarizing muscle relaxants namely tubocurarine, alcuronium, c-toxiferine and pancuronium in quantities of one-quarter or less of their muscle relaxant level. It is suggested that suxamethonium causes altered cardiac rhythm by stimulation of afferent vagal receptors, which action may be blocked by tubocurarine and similar drugs.
Suxamethonium is known to produce alterations in the rate and rhythm of the heart (Leigh et al., 1957; Telford and Keats, 1957; Martin, 1958; Bullough, 1959; Lupprian and Churchill-Davidson, 1960) . This effect may be blocked by atropine (Lupprian and Churchill-Davidson, 1960) or by the prior administration of small amounts of tubocurarine (Mathias and EvansProsser, 1968) . This paper reports the action of other nondepolarizing muscle relaxants on the alterations in rate and rhythm of the heart caused by suxamethonium.
METHOD
123 unselected patients (58 females and 65 males) with ages ranging from 14 to 67 years were given two intermittent doses of suxamethonium (100 mg) at varying intervals. Changes in the rate and rhythm of the heart occurring after the second dose of suxamethonium were recorded with an electrocardiogram.
The nature of the investigation was explained to each patient and their consent obtained in each case.
Premedication. All the patients were given papaveretum (10-20 mg) and hyoscine hydrobromide (0.2-0.4 mg) 1 hour prior to anaesthesia.
Anaesthesia. Prior to the induction of anaesthesia each patient was given the appropriate amount of non-depolarizing muscle relaxant calculated on the patient's body weight. After an interval of 2 minutes anaesthesia was induced with thiopentone (200-500 mg) and suxamethonium (100 mg). Lignocaine 4 per cent spray was applied to the trachea and vocal cords and intubation performed, following ventilation of the patient's lungs with 100 per cent oxygen. Artificial respiration was continued with nitrous oxide and oxygen mixture (2:1). When spontaneous respiration was fully re-established, a second injection of suxamethonium was given whilst a continuous recording was made on the electrocardiogram ( fig. 1) .
Changes in heart rate were measured during the period of greatest change and the rate deduced from the mean beat-to-beat interval over 5 beats. This was compared with a control rate obtained immediately prior to the second suxamethonium injection.
The patients have been divided into four groups, each group being given a different nondepolarizing muscle relaxant prior to induction of anaesthesia in each case.
Group A consisted of 34 patients who were given varying amounts of tubocurarine.
Group B consisted of 30 patients who were given varying amounts of alcuronium.
Group C consisted of 25 patients who were given varying amounts of c-toxiferine.
Group D consisted of 34 patients who were given varying amounts of pancuronium. 
RESULTS
It will be seen (tables I-IV; figs. 2-5) that, in the case of each non-depolarizing muscle relaxant drug investigated, there is a clear dose/response curve. At a dose level of 0.07 mg/kg (about 5 mg to the average adult), tubocurarine will prevent the occurrence of both bradycardia and arrhythmias following the administration of the second dose of suxamethonium.
In the same manner, alcuronium 3.5 mg, c-toxiferine 0.4 mg, pancuronium 2 mg, will also prevent the occurrence of the bradycardia of suxamethonium.
TABLE I
Effect of tubocurarine on heart rate after second dose of suxamethonium. 
DISCUSSION
In a previous study (Mathias and Evans-Prosser, 1968) it has been established that bradycardia may be expected in 80 per cent of cases following a second administration of suxamethonium. In the course of that study, an attempt was made to establish the site of action of suxamethonium on cardiac rhythm. One group of patients undergoing carotid angiography were given small amounts of suxamethonium directly into the common carotid artery and thus presumably into the pressor receptors of the carotid sinus. In over one-third of the patients in this group an immediate slowing of the heart was observed. The mechanism of this bradycardia is most important, for it may be completely prevented with small amounts of tubocurarine and other nondepolarizing muscle relaxants.
The slowing of the heart occurs only following and subsequent administrations in following the first injection in children (Leigh et aL, 1957; Telford and Keats, 1957) and digitalized ipatients (Dowdy and Fabian, 1963) . Furthermore, the bradycardia will only occur if the second injection of suxamethonium occurs within a critical period following the first injection (Mathias and Evans-Prosser, 1968 ). Lupprian and Churchill-Davidson (1960) showed that an intravenous injection of atropine was effective in preventing the occurrence of bradycardia during repeated injections of suxamethonium.
If atropine is believed to act principally at the sino-atrial node, it would appear that suxamethonium is acting at some point on the vagal pathway.
Since other workers have shown that ganglion blockade, with trimetaphan and hexamethonium (Williams et aL, 1961; Bennett, P. J., 1967, personal communication) , is also effective in blocking the cardiac actions of suxamethonium it is possible that the drug is exerting its action either at, or at a site proximal to, the cardiac ganglion (of the vagus nerve).
If tubocurarine is blocking the cardiac action of suxamethonium in a way similar to either atropine or hexamethonium it would be likely to produce a tachycardia. However, a tachycardia is rarely seen following injection of tubocurarine. Two possibilities therefore exist, to explain this potent action of non-depolarizing muscle relaxants. First of all, tubocurarine may prevent suxamethonium simulating the autonomic ganglion without itself affecting vagal impulses traversing the ganglion in a normal manner.
Alternatively, it may be postulated that suxamethonium is able to stimulate peripheral sensory receptors such as carotid sinus baroreceptors, and cause reflex bradycardia. It is supposed that tubocurarine is able to prevent suxamethonium stimulating these sensory re-ceptars without affecting the physiological response, i.e. it is able to block the s"'"Til»ft'ng action of suxamethonium (chemical response) whilst still permitting the receptor to transmit impulses signifying a change in arterial tension (mechanical response). Support for this latter theory was obtained from the results of intra-arterial injection close to the carotid sinus (Mathias and EvansProsser, 1968) . Suxamethonium is pharmacologically similar in many ways to acetylcholine.
On this assumption, the works of Daly (1954) , Douglas and Gray (1953) and Gray and Diamond (1957) draw a close analogy to the present investigations. Diamond (1955) and Gray and Diamond (1957) describe the stimulant action of acetylcholine on pressor receptors and other sensory receptors. Whilst acetylcholine is able to stimulate receptor organs, this action may be blocked by tubocurarine which does not affect normal physiological action.
It may be that suxamethonium acts directly upon the heart and in some instances diis is almost certainly so (Galindo and Davis, 1962; Bush et al., 1959; Tolmie^ Joyce and Mitchell, 1967) 
